drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00618 | DB00819 | 1,572 | 471 | [
"DDInter498",
"DDInter15"
] | Demeclocycline | Acetazolamide | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Minor | 0 | [
[
[
1572,
23,
471
]
],
[
[
1572,
23,
997
],
[
997,
40,
471
]
],
[
[
1572,
1,
1545
],
[
1545,
23,
471
]
],
[
[
1572,
40,
964
],
[
964,
... | [
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetazolamide"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methazolamide"
]... | Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Demeclocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a minor interaction that can limit clinical effects when... |
DB00073 | DB10315 | 1,394 | 1,137 | [
"DDInter1608",
"DDInter1127"
] | Rituximab | Measles virus vaccine live attenuated | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
1394,
25,
1137
]
],
[
[
1394,
64,
581
],
[
581,
25,
1137
]
],
[
[
1394,
63,
1184
],
[
1184,
25,
1137
]
],
[
[
1394,
25,
1064
],
[
1064... | [
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"... | Rituximab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may ... |
DB00346 | DB09020 | 472 | 28 | [
"DDInter44",
"DDInter212"
] | Alfuzosin | Bisacodyl | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
472,
24,
28
]
],
[
[
472,
21,
28666
],
[
28666,
60,
28
]
],
[
[
472,
24,
823
],
[
823,
63,
28
]
],
[
[
472,
25,
982
],
[
982,
63... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Alfuzosin",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"... | Alfuzosin (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Bisacodyl (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerba... |
DB08901 | DB15091 | 1,468 | 676 | [
"DDInter1492",
"DDInter1901"
] | Ponatinib | Upadacitinib | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1468,
25,
676
]
],
[
[
1468,
63,
1430
],
[
1430,
24,
676
]
],
[
[
1468,
24,
748
],
[
748,
24,
676
]
],
[
[
1468,
25,
283
],
[
283,
... | [
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleuc... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine a... |
DB06603 | DB08871 | 39 | 36 | [
"DDInter1387",
"DDInter666"
] | Panobinostat | Eribulin | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Major | 2 | [
[
[
39,
25,
36
]
],
[
[
39,
63,
122
],
[
122,
23,
36
]
],
[
[
39,
62,
1247
],
[
1247,
23,
36
]
],
[
[
39,
64,
519
],
[
519,
24,
... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
"Verapamil... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Eribulin
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulf... |
DB00375 | DB00595 | 1,037 | 1,545 | [
"DDInter433",
"DDInter1374"
] | Colestipol | Oxytetracycline | Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally o... | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Minor | 0 | [
[
[
1037,
23,
1545
]
],
[
[
1037,
62,
964
],
[
964,
1,
1545
]
],
[
[
1037,
23,
1620
],
[
1620,
1,
1545
]
],
[
[
1037,
25,
1096
],
[
1096,
... | [
[
[
"Colestipol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Colestipol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
... | Colestipol may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembles Oxytetracycline (Compound)
Colestipol may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline (Compound) resembles Oxytetracycline... |
DB00284 | DB00603 | 1,647 | 303 | [
"DDInter11",
"DDInter1137"
] | Acarbose | Medroxyprogesterone acetate | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Moderate | 1 | [
[
[
1647,
24,
303
]
],
[
[
1647,
24,
167
],
[
167,
1,
303
]
],
[
[
1647,
21,
28809
],
[
28809,
60,
303
]
],
[
[
1647,
63,
215
],
[
215,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Acarbose (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Medroxyprogesterone acetate (Compound)
Acarbo... |
DB00582 | DB08868 | 1,622 | 1,011 | [
"DDInter1946",
"DDInter737"
] | Voriconazole | Fingolimod | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1622,
25,
1011
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
1622,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
1622,
25,
578
],
[
57... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fin... | Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Voriconazole (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Voriconazole may lead to a major life threatening interaction when taken with Ticagrelor and Tic... |
DB11691 | DB11952 | 1,499 | 800 | [
"DDInter1258",
"DDInter612"
] | Naldemedine | Duvelisib | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
1499,
24,
800
]
],
[
[
1499,
24,
1476
],
[
1476,
63,
800
]
],
[
[
1499,
63,
267
],
[
267,
24,
800
]
],
[
[
1499,
24,
351
],
[
351,
... | [
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltr... |
DB00845 | DB09020 | 1,490 | 28 | [
"DDInter406",
"DDInter212"
] | Clofazimine | Bisacodyl | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1490,
24,
28
]
],
[
[
1490,
7,
6717
],
[
6717,
46,
28
]
],
[
[
1490,
21,
28809
],
[
28809,
60,
28
]
],
[
[
1490,
24,
823
],
[
823,
... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Clofazimine",
"{u} (Compound) upregulates {v} (Gene)",
"HERPUD1"
],
[
"HERPUD1",
"{u} (Gene) is upregulated by {... | Clofazimine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Bisacodyl (Compound)
Clofazimine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Bisacodyl (Compound)
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Tric... |
DB00366 | DB01168 | 1,594 | 1,053 | [
"DDInter600",
"DDInter1526"
] | Doxylamine | Procarbazine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1594,
25,
1053
]
],
[
[
1594,
21,
29119
],
[
29119,
60,
1053
]
],
[
[
1594,
24,
9
],
[
9,
63,
1053
]
],
[
[
1594,
24,
100
],
[
100,
... | [
[
[
"Doxylamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Haemolytic anaemia"
],
[
"Haemolytic anaemia",
"{u} (Side Effect) is... | Doxylamine (Compound) causes Haemolytic anaemia (Side Effect) and Haemolytic anaemia (Side Effect) is caused by Procarbazine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine may cause a moderate interaction that could exacerbat... |
DB09085 | DB15373 | 587 | 1,256 | [
"DDInter1779",
"DDInter1807"
] | Tetracaine | Tilmanocept | Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch. | Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)). | Moderate | 1 | [
[
[
587,
24,
1256
]
],
[
[
587,
23,
771
],
[
771,
62,
608
],
[
608,
24,
1256
]
],
[
[
587,
63,
1119
],
[
1119,
63,
608
],
[
608,
24,
... | [
[
[
"Tetracaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tilmanocept"
]
],
[
[
"Tetracaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
... | Tetracaine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tilmanocept
Tetra... |
DB01236 | DB06616 | 679 | 594 | [
"DDInter1664",
"DDInter224"
] | Sevoflurane | Bosutinib | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
679,
24,
594
]
],
[
[
679,
6,
8374
],
[
8374,
45,
594
]
],
[
[
679,
21,
29231
],
[
29231,
60,
594
]
],
[
[
679,
62,
112
],
[
112,
... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Sevoflurane",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Sevoflurane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Sevoflurane (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metron... |
DB00215 | DB01362 | 1,230 | 497 | [
"DDInter388",
"DDInter960"
] | Citalopram | Iohexol | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1230,
25,
497
]
],
[
[
1230,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1230,
24,
1574
],
[
1574,
63,
497
]
],
[
[
1230,
24,
999
],
[
999,... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Citalopram",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused b... | Citalopram (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
... |
DB00533 | DB00945 | 1,416 | 1,479 | [
"DDInter1613",
"DDInter20"
] | Rofecoxib | Acetylsalicylic acid | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
1416,
24,
1479
]
],
[
[
1416,
63,
1314
],
[
1314,
23,
1479
]
],
[
[
1416,
24,
714
],
[
714,
63,
1479
]
],
[
[
1416,
63,
1271
],
[
1271... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
]... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Iloprost an... |
DB00604 | DB09054 | 1,425 | 384 | [
"DDInter385",
"DDInter905"
] | Cisapride | Idelalisib | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
1425,
25,
384
]
],
[
[
1425,
25,
318
],
[
318,
23,
384
]
],
[
[
1425,
64,
1230
],
[
1230,
23,
384
]
],
[
[
1425,
24,
307
],
[
307,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u}... | Cisapride may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Cisapride may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a minor interac... |
DB00001 | DB06754 | 1,578 | 707 | [
"DDInter1037",
"DDInter471"
] | Lepirudin | Danaparoid | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
1578,
25,
707
]
],
[
[
1578,
23,
944
],
[
944,
62,
707
]
],
[
[
1578,
24,
298
],
[
298,
63,
707
]
],
[
[
1578,
24,
901
],
[
901,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Lepirudin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may c... |
DB00771 | DB01267 | 262 | 519 | [
"DDInter397",
"DDInter1381"
] | Clidinium | Paliperidone | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
262,
24,
519
]
],
[
[
262,
63,
1664
],
[
1664,
1,
519
]
],
[
[
262,
24,
924
],
[
924,
1,
519
]
],
[
[
262,
24,
1192
],
[
1192,
2... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Comp... |
DB00865 | DB09268 | 939 | 1,662 | [
"DDInter187",
"DDInter1464"
] | Benzphetamine | Picosulfuric acid | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
939,
24,
1662
]
],
[
[
939,
40,
1164
],
[
1164,
24,
1662
]
],
[
[
939,
64,
73
],
[
73,
24,
1662
]
],
[
[
939,
1,
1405
],
[
1405,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} ma... | Benzphetamine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Benzphetamine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may cause a moderate interaction that c... |
DB00009 | DB04865 | 1,271 | 4 | [
"DDInter56",
"DDInter1335"
] | Alteplase | Omacetaxine mepesuccinate | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
1271,
25,
4
]
],
[
[
1271,
24,
738
],
[
738,
63,
4
]
],
[
[
1271,
25,
39
],
[
39,
63,
4
]
],
[
[
1271,
25,
1213
],
[
1213,
24,
... | [
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Alteplase may lead to a major life threatening interaction when taken with Panobinostat and Panobino... |
DB00563 | DB09122 | 663 | 1,613 | [
"DDInter1174",
"DDInter1409"
] | Methotrexate | Peginterferon beta-1a | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
663,
24,
1613
]
],
[
[
663,
24,
671
],
[
671,
24,
1613
]
],
[
[
663,
63,
152
],
[
152,
24,
1613
]
],
[
[
663,
24,
975
],
[
975,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bose... |
DB00950 | DB12130 | 1,413 | 1,017 | [
"DDInter732",
"DDInter1094"
] | Fexofenadine | Lorlatinib | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1413,
24,
1017
]
],
[
[
1413,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
1413,
24,
1491
],
[
1491,
24,
1017
]
],
[
[
1413,
24,
971
],
[
971... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
... | Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and M... |
DB00526 | DB13139 | 1,555 | 1,032 | [
"DDInter1355",
"DDInter1063"
] | Oxaliplatin | Levosalbutamol | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1555,
24,
1032
]
],
[
[
1555,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1555,
24,
124
],
[
124,
24,
1032
]
],
[
[
1555,
25,
982
],
[
982,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Ca... | Oxaliplatin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib ma... |
DB11730 | DB14444 | 351 | 151 | [
"DDInter1588",
"DDInter924"
] | Ribociclib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
351,
24,
151
]
],
[
[
351,
63,
66
],
[
66,
24,
151
]
],
[
[
351,
25,
1619
],
[
1619,
24,
151
]
],
[
[
351,
64,
375
],
[
375,
24,... | [
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could e... | Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ribociclib may lead to a major life t... |
DB00055 | DB12500 | 834 | 283 | [
"DDInter605",
"DDInter714"
] | Drotrecogin alfa | Fedratinib | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
834,
25,
283
]
],
[
[
834,
25,
885
],
[
885,
24,
283
]
],
[
[
834,
24,
529
],
[
529,
24,
283
]
],
[
[
834,
25,
1564
],
[
1564,
2... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprosteno... | Drotrecogin alfa may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluv... |
DB00372 | DB09488 | 999 | 103 | [
"DDInter1793",
"DDInter23"
] | Thiethylperazine | Acrivastine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
999,
24,
103
]
],
[
[
999,
24,
1405
],
[
1405,
24,
103
]
],
[
[
999,
63,
357
],
[
357,
24,
103
]
],
[
[
999,
24,
418
],
[
418,
6... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprin... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01168 | DB09571 | 1,053 | 1,308 | [
"DDInter1526",
"DDInter1047"
] | Procarbazine | Levmetamfetamine (nasal) | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Levmetamfetamine is a member of amphetamines. | Moderate | 1 | [
[
[
1053,
24,
1308
]
],
[
[
1053,
63,
1052
],
[
1052,
24,
1629
],
[
1629,
24,
1308
]
],
[
[
1053,
24,
697
],
[
697,
24,
1629
],
[
1629,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levmetamfetamine"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Levmetamfetamine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blu... |
DB00598 | DB09340 | 1,523 | 1,013 | [
"DDInter1013",
"DDInter1895"
] | Labetalol | Tyropanoic acid | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image ... | Moderate | 1 | [
[
[
1523,
24,
1013
]
],
[
[
1523,
24,
777
],
[
777,
24,
1013
]
],
[
[
1523,
63,
1648
],
[
1648,
24,
1013
]
],
[
[
1523,
24,
777
],
[
777,
... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
],
[
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide and Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Alde... |
DB00213 | DB00529 | 837 | 789 | [
"DDInter1388",
"DDInter779"
] | Pantoprazole | Foscarnet | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Moderate | 1 | [
[
[
837,
24,
789
]
],
[
[
837,
21,
29785
],
[
29785,
60,
789
]
],
[
[
837,
24,
1297
],
[
1297,
63,
789
]
],
[
[
837,
1,
1215
],
[
1215,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Pantoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Abscess"
],
[
"Abscess",
"{u} (Side Effect) is cause... | Pantoprazole (Compound) causes Abscess (Side Effect) and Abscess (Side Effect) is caused by Foscarnet (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Fosc... |
DB00757 | DB01015 | 1,166 | 1,247 | [
"DDInter581",
"DDInter1724"
] | Dolasetron | Sulfamethoxazole | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Minor | 0 | [
[
[
1166,
23,
1247
]
],
[
[
1166,
6,
6017
],
[
6017,
45,
1247
]
],
[
[
1166,
21,
28804
],
[
28804,
60,
1247
]
],
[
[
1166,
64,
11
],
[
11,... | [
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Dolasetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compoun... | Dolasetron (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfamethoxazole (Compound)
Dolasetron (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Sulfamethoxazole (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Toremifene and Toremifene ... |
DB00405 | DB00494 | 128 | 1,533 | [
"DDInter517",
"DDInter646"
] | Dexbrompheniramine | Entacapone | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa conce... | Moderate | 1 | [
[
[
128,
24,
1533
]
],
[
[
128,
63,
1062
],
[
1062,
1,
1533
]
],
[
[
128,
24,
770
],
[
770,
63,
1533
]
],
[
[
128,
63,
701
],
[
701,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolcapone"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) resembles Entacapone (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate intera... |
DB06273 | DB06317 | 980 | 1,626 | [
"DDInter1824",
"DDInter630"
] | Tocilizumab | Elotuzumab | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
980,
24,
1626
]
],
[
[
980,
63,
973
],
[
973,
24,
1626
]
],
[
[
980,
24,
200
],
[
200,
63,
1626
]
],
[
[
980,
64,
1531
],
[
1531,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans an... |
DB00771 | DB01203 | 262 | 699 | [
"DDInter397",
"DDInter1255"
] | Clidinium | Nadolol | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
262,
24,
699
]
],
[
[
262,
24,
729
],
[
729,
1,
699
]
],
[
[
262,
63,
1442
],
[
1442,
24,
699
]
],
[
[
262,
24,
820
],
[
820,
63... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
"... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could ex... |
DB00620 | DB06335 | 175 | 761 | [
"DDInter1855",
"DDInter1646"
] | Triamcinolone | Saxagliptin | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
175,
24,
761
]
],
[
[
175,
6,
8374
],
[
8374,
45,
761
]
],
[
[
175,
21,
28966
],
[
28966,
60,
761
]
],
[
[
175,
23,
307
],
[
307,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Triamcinolone (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Saxagliptin (Compound)
Triamcinolone may cause a minor interaction that can l... |
DB01144 | DB11827 | 1,326 | 433 | [
"DDInter540",
"DDInter669"
] | Diclofenamide | Ertugliflozin | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1326,
24,
433
]
],
[
[
1326,
63,
959
],
[
959,
24,
433
]
],
[
[
1326,
24,
885
],
[
885,
24,
433
]
],
[
[
1326,
24,
1019
],
[
1019,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol a... |
DB00514 | DB01081 | 506 | 1,688 | [
"DDInter527",
"DDInter571"
] | Dextromethorphan | Diphenoxylate | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Subst... | Moderate | 1 | [
[
[
506,
24,
1688
]
],
[
[
506,
63,
576
],
[
576,
1,
1688
]
],
[
[
506,
24,
1118
],
[
1118,
1,
1688
]
],
[
[
506,
63,
194
],
[
194,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Diphenoxylate (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin and Difenoxin (Compound) resembles Diphenoxyla... |
DB00496 | DB00574 | 194 | 121 | [
"DDInter480",
"DDInter717"
] | Darifenacin | Fenfluramine | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
194,
24,
121
]
],
[
[
194,
25,
1670
],
[
1670,
63,
121
]
],
[
[
194,
24,
868
],
[
868,
63,
121
]
],
[
[
194,
63,
1018
],
[
1018,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Darifenacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglu... | Darifenacin may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may ... |
DB00981 | DB01591 | 1,528 | 667 | [
"DDInter1463",
"DDInter1696"
] | Physostigmine (ophthalmic) | Solifenacin | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1528,
24,
667
]
],
[
[
1528,
21,
28722
],
[
28722,
60,
667
]
],
[
[
1528,
24,
830
],
[
830,
63,
667
]
],
[
[
1528,
63,
104
],
[
104,
... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Physostigmine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is cau... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Physostigmine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Solifenacin (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Phenin... |
DB00158 | DB00564 | 356 | 1,236 | [
"DDInter771",
"DDInter293"
] | Folic acid | Carbamazepine | Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic aci... | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
356,
24,
1236
]
],
[
[
356,
24,
362
],
[
362,
1,
1236
]
],
[
[
356,
24,
1335
],
[
1335,
40,
1236
]
],
[
[
356,
21,
28695
],
[
28695,
... | [
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Carbamazepine (... |
DB00047 | DB09082 | 176 | 659 | [
"DDInter932",
"DDInter1934"
] | Insulin glargine | Vilanterol | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
176,
24,
659
]
],
[
[
176,
24,
1220
],
[
1220,
23,
659
]
],
[
[
176,
24,
88
],
[
88,
24,
659
]
],
[
[
176,
25,
839
],
[
839,
24,... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Metop... |
DB06700 | DB06704 | 643 | 247 | [
"DDInter511",
"DDInter952"
] | Desvenlafaxine | Iobenguane (I-131) | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
643,
37,
247
]
],
[
[
643,
6,
7390
],
[
7390,
45,
247
]
],
[
[
643,
21,
28787
],
[
28787,
60,
247
]
],
[
[
643,
63,
820
],
[
820,
... | [
[
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Desvenlafaxine",
"{u} (Compound) binds {v} (Gene)",
... | Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Desvenlafaxine may lead to a major life threatening interaction when taken with Iobenguane
Desvenlafaxine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Desvenlafaxine (Compo... |
DB00254 | DB01575 | 964 | 1,054 | [
"DDInter598",
"DDInter1005"
] | Doxycycline | Kaolin | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Moderate | 1 | [
[
[
964,
24,
1054
]
],
[
[
964,
40,
1620
],
[
1620,
24,
1054
]
],
[
[
964,
24,
1252
],
[
1252,
24,
1054
]
],
[
[
964,
1,
1669
],
[
1669,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kaolin"
]
],
[
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moder... | Doxycycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exa... |
DB00188 | DB00776 | 168 | 1,335 | [
"DDInter222",
"DDInter1360"
] | Bortezomib | Oxcarbazepine | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Minor | 0 | [
[
[
168,
23,
1335
]
],
[
[
168,
23,
126
],
[
126,
1,
1335
]
],
[
[
168,
25,
1236
],
[
1236,
1,
1335
]
],
[
[
168,
23,
902
],
[
902,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
... | Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Oxcarbazepine (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Carbamazepine and Carbamazepine (Compound) resembles Oxcarbazepine (Compound)
Bortezomi... |
DB00694 | DB11986 | 51 | 484 | [
"DDInter485",
"DDInter648"
] | Daunorubicin | Entrectinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
51,
24,
484
]
],
[
[
51,
23,
1247
],
[
1247,
23,
484
]
],
[
[
51,
24,
466
],
[
466,
62,
484
]
],
[
[
51,
24,
1539
],
[
1539,
24,... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],... | Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Daroluta... |
DB01254 | DB14783 | 1,213 | 287 | [
"DDInter484",
"DDInter574"
] | Dasatinib | Diroximel fumarate | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1213,
24,
287
]
],
[
[
1213,
63,
1101
],
[
1101,
24,
287
]
],
[
[
1213,
25,
384
],
[
384,
24,
287
]
],
[
[
1213,
64,
1220
],
[
1220,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dasatinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may ... |
DB04837 | DB09118 | 649 | 1,580 | [
"DDInter407",
"DDInter1711"
] | Clofedanol | Stiripentol | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
649,
24,
1580
]
],
[
[
649,
24,
1609
],
[
1609,
63,
1580
]
],
[
[
649,
63,
1688
],
[
1688,
24,
1580
]
],
[
[
649,
1,
820
],
[
820,
... | [
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
... | Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate ... |
DB00488 | DB06688 | 196 | 1,430 | [
"DDInter57",
"DDInter1677"
] | Altretamine | Sipuleucel-T | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
196,
24,
1430
]
],
[
[
196,
24,
869
],
[
869,
24,
1430
]
],
[
[
196,
25,
676
],
[
676,
63,
1430
]
],
[
[
196,
24,
713
],
[
713,
... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[... | Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Altretamine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may ... |
DB06186 | DB12364 | 1,439 | 1,421 | [
"DDInter969",
"DDInter200"
] | Ipilimumab | Betrixaban | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1439,
25,
1421
]
],
[
[
1439,
24,
637
],
[
637,
24,
1421
]
],
[
[
1439,
25,
990
],
[
990,
24,
1421
]
],
[
[
1439,
63,
305
],
[
305,
... | [
[
[
"Ipilimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
],
... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Ipilimumab may lead to a major life threatening interaction when t... |
DB00731 | DB04868 | 1,144 | 478 | [
"DDInter1269",
"DDInter1293"
] | Nateglinide | Nilotinib | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1144,
24,
478
]
],
[
[
1144,
6,
6017
],
[
6017,
45,
478
]
],
[
[
1144,
21,
28966
],
[
28966,
60,
478
]
],
[
[
1144,
24,
1247
],
[
1247... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)"... | Nateglinide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Nateglinide (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Nilotinib (Compound)
Nateglinide may cause a moderate interaction that could exacer... |
DB06212 | DB14568 | 165 | 982 | [
"DDInter1833",
"DDInter1000"
] | Tolvaptan | Ivosidenib | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
165,
24,
982
]
],
[
[
165,
63,
1101
],
[
1101,
23,
982
]
],
[
[
165,
63,
543
],
[
543,
24,
982
]
],
[
[
165,
23,
1135
],
[
1135,
... | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide... |
DB01268 | DB01320 | 1,151 | 651 | [
"DDInter1731",
"DDInter783"
] | Sunitinib | Fosphenytoin | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Major | 2 | [
[
[
1151,
25,
651
]
],
[
[
1151,
63,
307
],
[
307,
1,
651
]
],
[
[
1151,
64,
362
],
[
362,
1,
651
]
],
[
[
1151,
6,
8374
],
[
8374,
... | [
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Sunitinib may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Sunitinib (Compou... |
DB00197 | DB00959 | 1,324 | 1,486 | [
"DDInter1881",
"DDInter1191"
] | Troglitazone | Methylprednisolone | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1324,
24,
1486
]
],
[
[
1324,
24,
175
],
[
175,
40,
1486
]
],
[
[
1324,
24,
167
],
[
167,
1,
1486
]
],
[
[
1324,
24,
1072
],
[
1072,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resemb... |
DB01406 | DB11730 | 984 | 351 | [
"DDInter472",
"DDInter1588"
] | Danazol | Ribociclib | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
984,
24,
351
]
],
[
[
984,
62,
222
],
[
222,
23,
351
]
],
[
[
984,
1,
1561
],
[
1561,
24,
351
]
],
[
[
984,
63,
372
],
[
372,
24... | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Danazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Si... | Danazol may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Danazol (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exa... |
DB06317 | DB09122 | 1,626 | 1,613 | [
"DDInter630",
"DDInter1409"
] | Elotuzumab | Peginterferon beta-1a | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1626,
24,
1613
]
],
[
[
1626,
63,
671
],
[
671,
24,
1613
]
],
[
[
1626,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1626,
24,
287
],
[
287,
... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Cannabid... |
DB00280 | DB00938 | 494 | 455 | [
"DDInter575",
"DDInter1635"
] | Disopyramide | Salmeterol | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
494,
24,
455
]
],
[
[
494,
24,
688
],
[
688,
63,
455
]
],
[
[
494,
6,
8374
],
[
8374,
45,
455
]
],
[
[
494,
21,
28722
],
[
28722,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Disopyramide (... |
DB01042 | DB01206 | 1,307 | 37 | [
"DDInter1144",
"DDInter1086"
] | Melphalan | Lomustine | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
1307,
24,
37
]
],
[
[
1307,
5,
11555
],
[
11555,
44,
37
]
],
[
[
1307,
54,
19138
],
[
19138,
15,
37
]
],
[
[
1307,
21,
28722
],
[
2872... | [
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Melphalan",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) ... | Melphalan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lomustine (Compound)
Melphalan (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Lomustine (Compound)
Melphalan (Compound) causes Nausea (Side ... |
DB00835 | DB09420 | 100 | 1,074 | [
"DDInter245",
"DDInter953"
] | Brompheniramine | Iodide I-123 | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
100,
24,
1074
]
],
[
[
100,
24,
516
],
[
516,
24,
1074
]
],
[
[
100,
35,
849
],
[
849,
24,
1074
]
],
[
[
100,
63,
902
],
[
902,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Brompheniramine (Compound) resembles Mepyramine (Compound) and Brompheniramine may cause a modera... |
DB00443 | DB00912 | 251 | 473 | [
"DDInter195",
"DDInter1581"
] | Betamethasone | Repaglinide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
251,
24,
473
]
],
[
[
251,
6,
8374
],
[
8374,
45,
473
]
],
[
[
251,
18,
5245
],
[
5245,
57,
473
]
],
[
[
251,
21,
28876
],
[
28876,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound)
Betamethasone (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Repaglinide (Compound)
Betamethasone (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect... |
DB01124 | DB01377 | 1,411 | 1,283 | [
"DDInter1828",
"DDInter1119"
] | Tolbutamide | Magnesium oxide | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
1411,
24,
1283
]
],
[
[
1411,
63,
743
],
[
743,
23,
1283
]
],
[
[
1411,
24,
1592
],
[
1592,
62,
1283
]
],
[
[
1411,
24,
772
],
[
772,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Ne... |
DB00673 | DB09048 | 723 | 555 | [
"DDInter112",
"DDInter1284"
] | Aprepitant | Netupitant | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Moderate | 1 | [
[
[
723,
24,
555
]
],
[
[
723,
62,
1101
],
[
1101,
23,
555
]
],
[
[
723,
23,
466
],
[
466,
62,
555
]
],
[
[
723,
24,
283
],
[
283,
6... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Aprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutami... |
DB00652 | DB01156 | 234 | 593 | [
"DDInter1421",
"DDInter252"
] | Pentazocine | Bupropion | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
234,
25,
593
]
],
[
[
234,
21,
28905
],
[
28905,
60,
593
]
],
[
[
234,
24,
256
],
[
256,
62,
593
]
],
[
[
234,
63,
752
],
[
752,
... | [
[
[
"Pentazocine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Pentazocine",
"{u} (Compound) causes {v} (Side Effect)",
"Irritability"
],
[
"Irritability",
"{u} (Side Effect) is caused by {v... | Pentazocine (Compound) causes Irritability (Side Effect) and Irritability (Side Effect) is caused by Bupropion (Compound)
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Bupr... |
DB01115 | DB11718 | 336 | 927 | [
"DDInter1291",
"DDInter640"
] | Nifedipine | Encorafenib | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
336,
24,
927
]
],
[
[
336,
63,
1324
],
[
1324,
24,
927
]
],
[
[
336,
40,
84
],
[
84,
24,
927
]
],
[
[
336,
24,
1491
],
[
1491,
2... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Nifedipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction tha... |
DB01211 | DB09043 | 609 | 135 | [
"DDInter393",
"DDInter36"
] | Clarithromycin | Albiglutide | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
609,
24,
135
]
],
[
[
609,
64,
126
],
[
126,
23,
135
]
],
[
[
609,
63,
1647
],
[
1647,
23,
135
]
],
[
[
609,
24,
519
],
[
519,
2... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"War... | Clarithromycin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a... |
DB00876 | DB09268 | 1,414 | 1,662 | [
"DDInter658",
"DDInter1464"
] | Eprosartan | Picosulfuric acid | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1414,
24,
1662
]
],
[
[
1414,
24,
708
],
[
708,
24,
1662
]
],
[
[
1414,
63,
1573
],
[
1573,
24,
1662
]
],
[
[
1414,
24,
407
],
[
407,
... | [
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]... | Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Predniso... |
DB00041 | DB01359 | 1,648 | 729 | [
"DDInter38",
"DDInter1417"
] | Aldesleukin | Penbutolol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
1648,
24,
729
]
],
[
[
1648,
24,
461
],
[
461,
1,
729
]
],
[
[
1648,
24,
699
],
[
699,
40,
729
]
],
[
[
1648,
24,
552
],
[
552,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Aldesleuki... |
DB00820 | DB01240 | 402 | 885 | [
"DDInter1736",
"DDInter657"
] | Tadalafil | Epoprostenol | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibito... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Minor | 0 | [
[
[
402,
23,
885
]
],
[
[
402,
62,
1061
],
[
1061,
1,
885
]
],
[
[
402,
10,
11573
],
[
11573,
49,
885
]
],
[
[
402,
21,
28684
],
[
28684,
... | [
[
[
"Tadalafil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epoprostenol"
]
],
[
[
"Tadalafil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Treprostinil"
],
[
... | Tadalafil may cause a minor interaction that can limit clinical effects when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Tadalafil (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Epoprostenol (Compound)
Tadalafil (Compound)... |
DB00673 | DB01149 | 723 | 851 | [
"DDInter112",
"DDInter1274"
] | Aprepitant | Nefazodone | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
723,
24,
851
]
],
[
[
723,
24,
673
],
[
673,
40,
851
]
],
[
[
723,
63,
827
],
[
827,
40,
851
]
],
[
[
723,
6,
8374
],
[
8374,
45... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Nefazodone (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Nefazodone (Compound... |
DB00655 | DB11979 | 559 | 1,320 | [
"DDInter682",
"DDInter625"
] | Estrone | Elagolix | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
559,
24,
1320
]
],
[
[
559,
24,
129
],
[
129,
24,
1320
]
],
[
[
559,
24,
159
],
[
159,
63,
1320
]
],
[
[
559,
1,
35
],
[
35,
24,... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"E... | Estrone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotre... |
DB00041 | DB00999 | 1,648 | 504 | [
"DDInter38",
"DDInter883"
] | Aldesleukin | Hydrochlorothiazide | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Moderate | 1 | [
[
[
1648,
24,
504
]
],
[
[
1648,
24,
1326
],
[
1326,
40,
504
]
],
[
[
1648,
24,
178
],
[
178,
1,
504
]
],
[
[
1648,
24,
1264
],
[
1264,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles H... |
DB00903 | DB09564 | 1,680 | 1,296 | [
"DDInter686",
"DDInter930"
] | Etacrynic acid | Insulin degludec | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1680,
24,
1296
]
],
[
[
1680,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1680,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
1680,
62,
964
],
[
964... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Metfo... |
DB06186 | DB09121 | 1,439 | 1,328 | [
"DDInter969",
"DDInter140"
] | Ipilimumab | Aurothioglucose | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Moderate | 1 | [
[
[
1439,
24,
1328
]
],
[
[
1439,
63,
367
],
[
367,
24,
1328
]
],
[
[
1439,
24,
310
],
[
310,
24,
1328
]
],
[
[
1439,
24,
148
],
[
148,
... | [
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01192 | DB08895 | 560 | 976 | [
"DDInter1372",
"DDInter1825"
] | Oxymorphone | Tofacitinib | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
560,
24,
976
]
],
[
[
560,
40,
314
],
[
314,
24,
976
]
],
[
[
560,
24,
407
],
[
407,
63,
976
]
],
[
[
560,
75,
475
],
[
475,
24,... | [
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Oxymorphone",
"{u} (Compound) resembles {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a mode... | Oxymorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacer... |
DB00252 | DB00471 | 362 | 201 | [
"DDInter1460",
"DDInter1242"
] | Phenytoin | Montelukast | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Moderate | 1 | [
[
[
362,
24,
201
]
],
[
[
362,
6,
3486
],
[
3486,
45,
201
]
],
[
[
362,
7,
6952
],
[
6952,
46,
201
]
],
[
[
362,
21,
28787
],
[
28787,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Phenytoin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Montelukast (Compound)
Phenytoin (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Montelukast (Compound)
Phenytoin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Montelukast (Compound)
Ph... |
DB05239 | DB11601 | 866 | 1,270 | [
"DDInter425",
"DDInter1889"
] | Cobimetinib | Tuberculin purified protein derivative | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
866,
24,
1270
]
],
[
[
866,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
866,
63,
869
],
[
869,
24,
1270
]
],
[
[
866,
64,
1064
],
[
1064,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Cobimetinib may cause a moderate interaction that could exacerbate diseases when ... |
DB00104 | DB06655 | 966 | 5 | [
"DDInter1323",
"DDInter1077"
] | Octreotide | Liraglutide | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
966,
24,
5
]
],
[
[
966,
24,
1252
],
[
1252,
23,
5
]
],
[
[
966,
24,
245
],
[
245,
24,
5
]
],
[
[
966,
63,
176
],
[
176,
24,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride ... |
DB00957 | DB06206 | 873 | 1,268 | [
"DDInter1314",
"DDInter1719"
] | Norgestimate | Sugammadex | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat mod... | Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general ane... | Major | 2 | [
[
[
873,
25,
1268
]
],
[
[
873,
40,
615
],
[
615,
64,
1268
]
],
[
[
873,
40,
1657
],
[
1657,
25,
1268
]
],
[
[
873,
40,
615
],
[
615,
... | [
[
[
"Norgestimate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sugammadex"
]
],
[
[
"Norgestimate",
"{u} (Compound) resembles {v} (Compound)",
"Norelgestromin"
],
[
"Norelgestromin",
"{u} may lead to a major li... | Norgestimate (Compound) resembles Norelgestromin (Compound) and Norelgestromin may lead to a major life threatening interaction when taken with Sugammadex
Norgestimate (Compound) resembles Desogestrel (Compound) and Desogestrel may lead to a major life threatening interaction when taken with Sugammadex
Norgestimate (Co... |
DB00209 | DB00577 | 352 | 1,295 | [
"DDInter1886",
"DDInter1908"
] | Trospium | Valaciclovir | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Valaciclovir (valacyclovir), also known as _Valtrex_, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member ... | Moderate | 1 | [
[
[
352,
24,
1295
]
],
[
[
352,
24,
563
],
[
563,
40,
1295
]
],
[
[
352,
21,
28868
],
[
28868,
60,
1295
]
],
[
[
352,
24,
752
],
[
752,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valaciclovir"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valaciclovir (Compound)
Trospium (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Valaciclovir (Compound)
Trospium may cause a moderate interactio... |
DB00176 | DB00835 | 529 | 100 | [
"DDInter770",
"DDInter245"
] | Fluvoxamine | Brompheniramine | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
529,
24,
100
]
],
[
[
529,
24,
832
],
[
832,
24,
100
]
],
[
[
529,
24,
649
],
[
649,
63,
100
]
],
[
[
529,
6,
8374
],
[
8374,
45... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clofed... |
DB05294 | DB09268 | 1,069 | 1,662 | [
"DDInter1917",
"DDInter1464"
] | Vandetanib | Picosulfuric acid | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Major | 2 | [
[
[
1069,
25,
1662
]
],
[
[
1069,
63,
1252
],
[
1252,
23,
1662
]
],
[
[
1069,
64,
1164
],
[
1164,
24,
1662
]
],
[
[
1069,
25,
484
],
[
484... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxi... | Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Vandetanib may lead to a major life threatening interaction when taken with Trimipramine and Trimipramine may cau... |
DB00398 | DB00927 | 79 | 1,559 | [
"DDInter1702",
"DDInter712"
] | Sorafenib | Famotidine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
79,
24,
1559
]
],
[
[
79,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
79,
18,
1918
],
[
1918,
57,
1559
]
],
[
[
79,
21,
28826
],
[
28826,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",... | Sorafenib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Sorafenib (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Famotidine (Compound)
Sorafenib (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Sorafen... |
DB00397 | DB09241 | 1,466 | 1,629 | [
"DDInter1458",
"DDInter1186"
] | Phenylpropanolamine | Methylene blue | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Major | 2 | [
[
[
1466,
25,
1629
]
],
[
[
1466,
24,
1052
],
[
1052,
24,
1629
]
],
[
[
1466,
63,
1000
],
[
1000,
24,
1629
]
],
[
[
1466,
35,
584
],
[
584... | [
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with G... |
DB00675 | DB08865 | 888 | 1,593 | [
"DDInter1744",
"DDInter448"
] | Tamoxifen | Crizotinib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
888,
25,
1593
]
],
[
[
888,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
888,
7,
7260
],
[
7260,
46,
1593
]
],
[
[
888,
18,
13230
],
[
13230,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotini... | Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Tamoxifen (Compound) upregulates MVD (Gene) and MVD (Gene) is upregulated by Crizotinib (Compound)
Tamoxifen (Compound) downregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Crizotinib (Compound)
Tamoxifen (Compound) ... |
DB00046 | DB00938 | 1,179 | 455 | [
"DDInter940",
"DDInter1635"
] | Insulin lispro | Salmeterol | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1179,
24,
455
]
],
[
[
1179,
24,
1523
],
[
1523,
25,
455
]
],
[
[
1179,
24,
688
],
[
688,
63,
455
]
],
[
[
1179,
24,
167
],
[
167,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may ... |
DB00328 | DB11817 | 831 | 1,259 | [
"DDInter921",
"DDInter165"
] | Indomethacin | Baricitinib | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
831,
24,
1259
]
],
[
[
831,
24,
1274
],
[
1274,
24,
1259
]
],
[
[
831,
40,
24
],
[
24,
24,
1259
]
],
[
[
831,
24,
384
],
[
384,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Indomethacin (Compound) resembles Tolmetin (Compound) and Tolmetin may cause a moderate interaction that ... |
DB00374 | DB01018 | 1,061 | 1,364 | [
"DDInter1852",
"DDInter847"
] | Treprostinil | Guanfacine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Moderate | 1 | [
[
[
1061,
24,
1364
]
],
[
[
1061,
24,
1512
],
[
1512,
1,
1364
]
],
[
[
1061,
6,
6017
],
[
6017,
45,
1364
]
],
[
[
1061,
21,
28757
],
[
287... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Guanfacine (Compound)
Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Guanfacine (Compound)
Treprostinil (Compound) causes Dyspepsia (Side Effect) and Dys... |
DB00280 | DB00741 | 494 | 167 | [
"DDInter575",
"DDInter885"
] | Disopyramide | Hydrocortisone | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
494,
24,
167
]
],
[
[
494,
24,
1220
],
[
1220,
40,
167
]
],
[
[
494,
24,
870
],
[
870,
1,
167
]
],
[
[
494,
6,
8374
],
[
8374,
4... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resemble... |
DB04575 | DB06404 | 35 | 1,514 | [
"DDInter1555",
"DDInter869"
] | Quinestrol | Human C1-esterase inhibitor | The 3-cyclopentyl ether of ethinyl estradiol. | C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.[L16586, L16606] This drug is indicated for prophylaxis and... | Moderate | 1 | [
[
[
35,
24,
1514
]
],
[
[
35,
40,
1438
],
[
1438,
24,
1514
]
],
[
[
35,
1,
984
],
[
984,
24,
1514
]
],
[
[
35,
25,
350
],
[
350,
64,... | [
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Quinestrol",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
],
[
"Estradiol",
"{u} may ... | Quinestrol (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Quinestrol (Compound) resembles Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Hu... |
DB00008 | DB00704 | 491 | 267 | [
"DDInter1407",
"DDInter1263"
] | Peginterferon alfa-2a | Naltrexone | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
491,
24,
267
]
],
[
[
491,
24,
522
],
[
522,
24,
267
]
],
[
[
491,
24,
850
],
[
850,
63,
267
]
],
[
[
491,
25,
72
],
[
72,
63,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafir... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00060 | DB00795 | 912 | 50 | [
"DDInter947",
"DDInter1725"
] | Interferon beta-1a | Sulfasalazine | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Moderate | 1 | [
[
[
912,
24,
50
]
],
[
[
912,
24,
161
],
[
161,
1,
50
]
],
[
[
912,
63,
305
],
[
305,
24,
50
]
],
[
[
912,
24,
546
],
[
546,
63,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadia... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase... |
DB01069 | DB09420 | 401 | 1,074 | [
"DDInter1533",
"DDInter953"
] | Promethazine | Iodide I-123 | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
401,
24,
1074
]
],
[
[
401,
24,
516
],
[
516,
24,
1074
]
],
[
[
401,
63,
902
],
[
902,
24,
1074
]
],
[
[
401,
62,
1247
],
[
1247,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clobaza... |
DB00692 | DB01037 | 274 | 1,161 | [
"DDInter1448",
"DDInter1653"
] | Phentolamine | Selegiline | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Moderate | 1 | [
[
[
274,
24,
1161
]
],
[
[
274,
24,
551
],
[
551,
1,
1161
]
],
[
[
274,
21,
28722
],
[
28722,
60,
1161
]
],
[
[
274,
62,
176
],
[
176,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
... | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Phentolamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Selegiline (Compound)
Phentolamine may cause a minor interaction tha... |
DB00734 | DB06691 | 1,664 | 849 | [
"DDInter1605",
"DDInter1155"
] | Risperidone | Mepyramine | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1664,
24,
849
]
],
[
[
1664,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1664,
24,
272
],
[
272,
24,
849
]
],
[
[
1664,
6,
12523
],
[
12523,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine an... |
DB00348 | DB00675 | 254 | 888 | [
"DDInter1300",
"DDInter1744"
] | Nitisinone | Tamoxifen | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
254,
24,
888
]
],
[
[
254,
21,
29152
],
[
29152,
60,
888
]
],
[
[
254,
24,
469
],
[
469,
62,
888
]
],
[
[
254,
63,
1648
],
[
1648,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Thirst"
],
[
"Thirst",
"{u} (Side Effect) is caused by {... | Nitisinone (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Tamoxifen (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine and Bromocriptine may cause a minor interaction that can limit clinical effects when taken with Tamoxifen
... |
DB00384 | DB13620 | 1,275 | 948 | [
"DDInter1859",
"DDInter1499"
] | Triamterene | Potassium gluconate | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Major | 2 | [
[
[
1275,
25,
948
]
],
[
[
1275,
24,
848
],
[
848,
24,
948
]
],
[
[
1275,
24,
848
],
[
848,
63,
1027
],
[
1027,
24,
948
]
],
[
[
1275,
... | [
[
[
"Triamterene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen an... |
DB00364 | DB00448 | 417 | 1,215 | [
"DDInter1717",
"DDInter1022"
] | Sucralfate | Lansoprazole | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Moderate | 1 | [
[
[
417,
24,
1215
]
],
[
[
417,
21,
28882
],
[
28882,
60,
1215
]
],
[
[
417,
62,
1031
],
[
1031,
23,
1215
]
],
[
[
417,
63,
1324
],
[
1324... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
],
[
[
"Sucralfate",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increase... | Sucralfate (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Lansoprazole (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a minor interaction that can limit clin... |
DB00421 | DB01240 | 443 | 885 | [
"DDInter1707",
"DDInter657"
] | Spironolactone | Epoprostenol | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
443,
24,
885
]
],
[
[
443,
63,
1061
],
[
1061,
1,
885
]
],
[
[
443,
21,
28921
],
[
28921,
60,
885
]
],
[
[
443,
24,
1512
],
[
1512,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Spironolactone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Epoprostenol (Compound)
Spironolactone may cause a m... |
DB01157 | DB08826 | 304 | 1,292 | [
"DDInter1875",
"DDInter489"
] | Trimetrexate | Deferiprone | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
304,
25,
1292
]
],
[
[
304,
21,
28722
],
[
28722,
60,
1292
]
],
[
[
304,
63,
482
],
[
482,
25,
1292
]
],
[
[
304,
24,
4
],
[
4,
... | [
[
[
"Trimetrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Trimetrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compo... | Trimetrexate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Deferiprone (Compound)
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Trimetrexat... |
DB00580 | DB01097 | 311 | 1,377 | [
"DDInter1910",
"DDInter1033"
] | Valdecoxib | Leflunomide | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
311,
25,
1377
]
],
[
[
311,
24,
126
],
[
126,
24,
1377
]
],
[
[
311,
24,
1411
],
[
1411,
63,
1377
]
],
[
[
311,
63,
245
],
[
245,
... | [
[
[
"Valdecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutam... |
DB01210 | DB09132 | 668 | 492 | [
"DDInter1050",
"DDInter797"
] | Levobunolol (ophthalmic) | Gadoteric acid | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA). It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium (Gd3+). Gadoterate meglumine has one o... | Moderate | 1 | [
[
[
668,
24,
492
]
],
[
[
668,
1,
699
],
[
699,
24,
492
]
],
[
[
668,
40,
461
],
[
461,
24,
492
]
],
[
[
668,
1,
699
],
[
699,
40,
... | [
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoteric acid"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound)",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a moderat... | Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol (Compound) resembles Nadolol (Compound) and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Levobunolol (Compound) resembles Timolol (Compound) an... |
DB01018 | DB11827 | 1,364 | 433 | [
"DDInter847",
"DDInter669"
] | Guanfacine | Ertugliflozin | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1364,
24,
433
]
],
[
[
1364,
40,
390
],
[
390,
24,
433
]
],
[
[
1364,
63,
251
],
[
251,
24,
433
]
],
[
[
1364,
24,
820
],
[
820,
... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Guanfacine",
"{u} (Compound) resembles {v} (Compound)",
"Guanabenz"
],
[
"Guanabenz",
"{u} may cause a modera... | Guanfacine (Compound) resembles Guanabenz (Compound) and Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction tha... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.